EP Patent

EP0236940A2 — Alpha-heterocycle substituted tolunitriles

Assigned to Novartis AG · Expires 1987-09-16 · 39y expired

What this patent protects

Compounds of the formula I wherein the groups R, R 0 , R 1 , R 2 and W are as defined in the specification, exhibit valuable pharmacological properties, especially as aromatase inhibitors.

USPTO Abstract

Compounds of the formula I wherein the groups R, R 0 , R 1 , R 2 and W are as defined in the specification, exhibit valuable pharmacological properties, especially as aromatase inhibitors.

Drugs covered by this patent

osilodrostat-phosphate (OSILODROSTAT PHOSPHATE)

Patent Metadata

Patent number: EP0236940A2
Jurisdiction: EP
Classification: —
Expires: 1987-09-16
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.